Clinical Trials Logo

Clinical Trial Summary

Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01303952
Study type Interventional
Source University Hospital, Essen
Contact
Status Completed
Phase Phase 2
Start date January 2011
Completion date June 2015

See also
  Status Clinical Trial Phase
Suspended NCT05096403 - A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Phase 3
Completed NCT05132127 - Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan Phase 3
Completed NCT03347422 - A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion Phase 3
Completed NCT00960713 - The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders N/A
Completed NCT00373594 - Therapy for Chronic Cold Agglutinin Disease Phase 2
Recruiting NCT05931718 - Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
Recruiting NCT05757570 - An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias Phase 1/Phase 2
Completed NCT02689986 - Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Phase 2
Completed NCT03226678 - Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD) Phase 2